Intended Use: MYCN (N-MYC) gene amplification
MYCN expression is associated with the maintenance of self-renewal capacity and the pluripotent status of stem cells. Dysregulation of MYCN contributes to the development of different kinds of childhood tumors including neuroblastoma, medulloblastoma, rhabdomyosarcoma and Wilms tumor. MYCN is also involved in the development of some adulthood neoplasms such as prostate and lung cancer.
Specimen Required
Paraffin-embed tissue (3–4-micron thick sections in positively charged/silanized slides).
Patient Preparation
- Sample collection: Tumor tissue (FFPE tissue block). Submit block/slides along with the corresponding Histopathology Report.
- Specimen preparation: Formalin fix (10 percent neutral buffered formalin) and paraffin-embed tissue (3–4-micron thick sections). Fixative duration: 6-48 hours.
- Storage/Transport Temperature: Room temperature. Protect paraffin block from excessive heat. Also acceptable: Refrigerated. Ship in cooled container during summer months.
- Unacceptable Conditions: Paraffin block with no tumor tissue remaining. Specimens fixed in any fixative other than 10 percent neutral buffered formalin. Decalcified specimens. Specimens with fixation delayed for more than one hour. Tissue fixed or less than 6 hours of greater than 48 hours.
- Remarks
- Stability: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
Methodology
Fluorescence in situ Hybridization (FISH)
Sample received to report Turnaround time (TAT)
5 working days
Reference Interval
————-
Interpretive Data
The most recent WHO classification of Tumours of Hematopoietic and Lymphoid Tissues (Revised 5th edition) is used for interpretation criteria for evaluating MYCN (N-MYC) gene amplification status.
Resources
- Additional Technical Information
- Test Request Form
Sample Reports
- Enhanced Report
- See report